Number of negative lymph nodes can predict survival after postmastectomy radiotherapy according to different XXXX subtypes.

@entity1 @entity0 @entity1349
PURPOSE: To assess the prognostic value of the number of negative lymph nodes (NLNs) in @entity0 @entity1 with positive axillary lymph nodes after mastectomy and its predictive value for radiotherapy efficacy of different @entity0 subtypes (BCS). METHODS: The records of 1,260 @entity0 @entity1 with positive axillary lymph nodes who received mastectomy between January 1998 and December 2007 were reviewed. The prognostic impact and predictive value of the number of NLNs with respect to locoregional recurrence-free survival (LRFS), disease-free survival (DFS), and @entity1349 ( @entity1349 ) were analyzed. RESULTS: The median follow-up time was 58 months, and 444 @entity1 (35.2%) received postmastectomy radiotherapy (PMRT). Univariate and multivariate Cox survival analysis indicated the number of NLNs was an independent prognostic factor of LRFS, DFS, and @entity1349 . @entity1 with a higher number of NLNs had better survival. PMRT improved the LRFS of @entity1 with  <= 8 NLNs ( p < 0.001), while failing to improve the LRFS of @entity1 with > 8 NLNs (p = 0.075). In @entity1 with luminal A subtype, PMRT improved the LRFS, DFS, and @entity1349 of @entity1 with  <= 8 NLNs, but in @entity1 with > 8 NLNs only the LRFS was improved. For @entity1 with luminal B subtype, PMRT only improved the LRFS of @entity1 with  <= 8 NLNs. The number of NLNs had no predictive value for the efficacy with PMRT in Her2+ and triple-negative subtypes. CONCLUSIONS: The number of NLNs is a prognostic indicator in @entity1 with @entity0 , and it can predict the efficacy of PMRT according to different BCS.
